Redeye leaves a comment following OncoZenge’s announcement of conditional acceptance of its Clinical Trial Application (CTA) for the pivotal Phase III study of BupiZenge in Europe. We are encouraged to see that the company has successfully addressed regulatory questions and progressed the application to near-final approval, marking an important step as OncoZenge transitions from preparation to execution of its registrational trial.
LÄS MER
